Brokerages Set Keros Therapeutics, Inc. (NASDAQ:KROS) Target Price at $42.33
Shares of Keros Therapeutics, Inc. (NASDAQ:KROS – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the fourteen analysts that are presently covering the stock, Marketbeat reports. Six equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The average […]
Shares of Keros Therapeutics, Inc. (NASDAQ:KROS – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the fourteen analysts that are presently covering the stock, Marketbeat reports. Six equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The average […]
